CO2022018364A2 - Preparación y purificación de igg hipersialilada - Google Patents

Preparación y purificación de igg hipersialilada

Info

Publication number
CO2022018364A2
CO2022018364A2 CONC2022/0018364A CO2022018364A CO2022018364A2 CO 2022018364 A2 CO2022018364 A2 CO 2022018364A2 CO 2022018364 A CO2022018364 A CO 2022018364A CO 2022018364 A2 CO2022018364 A2 CO 2022018364A2
Authority
CO
Colombia
Prior art keywords
hypersialylated
igg
purification
preparation
purifying
Prior art date
Application number
CONC2022/0018364A
Other languages
English (en)
Spanish (es)
Inventor
John Schaeck
Steffen Graham
Radouane Zouaoui
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CO2022018364A2 publication Critical patent/CO2022018364A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Water Supply & Treatment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CONC2022/0018364A 2020-05-19 2022-12-17 Preparación y purificación de igg hipersialilada CO2022018364A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063026875P 2020-05-19 2020-05-19
PCT/US2021/033156 WO2021236769A1 (en) 2020-05-19 2021-05-19 Preparation and purification of hypersialylated igg

Publications (1)

Publication Number Publication Date
CO2022018364A2 true CO2022018364A2 (es) 2022-12-30

Family

ID=78708028

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0018364A CO2022018364A2 (es) 2020-05-19 2022-12-17 Preparación y purificación de igg hipersialilada

Country Status (11)

Country Link
US (1) US20230193339A1 (https=)
EP (1) EP4153617A4 (https=)
JP (1) JP2023526527A (https=)
KR (1) KR20230012560A (https=)
CN (1) CN115715296A (https=)
AU (1) AU2021275117A1 (https=)
BR (1) BR112022023377A2 (https=)
CA (1) CA3182023A1 (https=)
CO (1) CO2022018364A2 (https=)
MX (1) MX2022014520A (https=)
WO (1) WO2021236769A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022023334A2 (pt) * 2020-05-19 2022-12-20 Momenta Pharmaceuticals Inc Imunoglobulina hipersialilada

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113604A2 (en) * 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
PH12012502193A1 (en) * 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
AU2011290672B2 (en) * 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
EP2877589B1 (en) * 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
EP2935610A4 (en) * 2012-12-20 2016-08-31 Medimmune Llc METHODS OF USING ION EXCHANGE CHROMATOGRAPHY TO CONTROL GLYCOFORM RATES WITH HIGH MANNOSIS
WO2014144621A2 (en) * 2013-03-15 2014-09-18 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
CN104327180A (zh) * 2013-07-23 2015-02-04 天士力制药集团股份有限公司 一种重组人血小板衍生生长因子bb的纯化方法

Also Published As

Publication number Publication date
JP2023526527A (ja) 2023-06-21
CA3182023A1 (en) 2021-11-25
CN115715296A (zh) 2023-02-24
AU2021275117A1 (en) 2022-12-01
BR112022023377A2 (pt) 2022-12-20
EP4153617A1 (en) 2023-03-29
MX2022014520A (es) 2023-03-03
KR20230012560A (ko) 2023-01-26
EP4153617A4 (en) 2024-11-20
US20230193339A1 (en) 2023-06-22
WO2021236769A1 (en) 2021-11-25

Similar Documents

Publication Publication Date Title
MX2025009360A (es) Medios y metodo para preparar vectores virales y usos de los mismos
MX2020013583A (es) Anticuerpos il-11.
JOP20230312A1 (ar) أجسام مضادة لـ ccr8 واستخداماتها
MX2022005839A (es) Compuestos utiles como inhibidores de la proteina helios.
CO2021003724A2 (es) Proteínas de fijación a sirpα y métodos de uso de estas
EA202092605A1 (ru) Антитела к ил-11ra
EA201890817A1 (ru) Кристаллические формы бета-никотинамида мононуклеотида
MX2021009891A (es) Metodos para purificar polisacaridos bacterianos.
BR112015019879A2 (pt) Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas
EP3978102A4 (en) Forward osmosis membrane, forward osmosis membrane module, and manufacturing method thereof
ECSP21021189A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
MX2023007003A (es) Antigenos especificos de tejidos para la inmunoterapia del cancer.
MX2021010665A (es) Metodos de tratamiento de amiloidosis al.
PL439808A1 (pl) Sposoby i kompozycje hodowli komórkowych do produkcji przeciwciał
MX2021001129A (es) Metodo de purificacion de antigenos.
CL2025002873A1 (es) Anticuerpos anti-cd19 y estructuras car-t
CO2022016670A2 (es) Inmunoglobulina hipersialilada
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
ECSP22041860A (es) Anticuerpos contra el virus de la fiebre amarilla y métodos de su generación y uso
CO2022018364A2 (es) Preparación y purificación de igg hipersialilada
JOP20230034A1 (ar) مثبطات إفراز البروتين
EA202191779A1 (ru) Способ получения антраниламидов
CO2022019225A2 (es) Anticuerpos anti-hbv y métodos de uso
EA202190699A1 (ru) Альтернативные способы получения тубулизинов и их промежуточных соединений
IL313212A (en) Solid state forms of tavapadon and processes for preparation thereof